COTA
COTA, Baptist Health South Florida, and PreciseDx Announce Collaboration on the AI-Enabled Breast Cancer Recurrence Risk Assessment, PreciseBreast™
“AI has the potential to augment human learning and improve the accuracy and precision of cancer diagnostics and treatments,” said Dr. C.K. Wang, chief medical officer, COTA. “It is critical that we evaluate these tools against the current standard of care to validate their efficacy and build trust in AI and new technologies.”
